지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.12
- 수록면
- 51 - 58 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: The study investigated correlations between adenosine triphosphate-based chemotherapy response assay (ATP-CRA) and clinical response after first line chemotherapy for metastatic colorectal cancer patients.
Methods: From June 2009 to June 2012, 24 patients were enrolled in this study. ATP-CRA was performed to evaluate the chemosensitivities of three combination anticancer drugs such as 5-fluorouracil (FU)+oxaliplatin and irinotecan, and capecitabine+oxaliplatin for metastatic colorectal cancer. A sensitive group (SG) and resistant group (RG) for chemotherapy regimen (oxaliplatin+5-FU+leucovorin [FOLFOX], n=14; oxaliplatin+capecitabine [CapeOx], n=2; irinotecan+5-FU+leucovorin [FOLFIRI], n=8) was defined as cut-off value 30%. The outcomes were a correlation between the ATP-CRA results and the clinical response and progression-free survival.
Results: Patients were dichotomized into the SG (19 patients) and RG (5 patients) groups. There was no difference between groups, in terms of regimen, frequency and interval of chemotherapy. The disease control rate after first response evaluation was not shown statistically difference (89.5% in SG and 60.0% in RG, respectively, P=0.15). And there was also no significance in second and third response evaluation. The median progression-free month were 7.0 (range, 2–27 month) and 5.0 (range, 3–12 month), respectively and shown marginal significance. However, there was no statistical difference in progression-free survival curve (P=0.16). Sensitivity, specificity, positive prediction rate and negative prediction rage for disease control after first response was 85.0%, 50.0%, 89.5%, and 40.0%.
Conclusion: Although ATP-CRA may be helpful in predicting chemotherapy response in metastatic colorectal cancer, there was not conclusive. Therefore, we recommend further clinical studies to confirm the efficacy of chemoresponse assay for metastatic colorectal cancer.
Methods: From June 2009 to June 2012, 24 patients were enrolled in this study. ATP-CRA was performed to evaluate the chemosensitivities of three combination anticancer drugs such as 5-fluorouracil (FU)+oxaliplatin and irinotecan, and capecitabine+oxaliplatin for metastatic colorectal cancer. A sensitive group (SG) and resistant group (RG) for chemotherapy regimen (oxaliplatin+5-FU+leucovorin [FOLFOX], n=14; oxaliplatin+capecitabine [CapeOx], n=2; irinotecan+5-FU+leucovorin [FOLFIRI], n=8) was defined as cut-off value 30%. The outcomes were a correlation between the ATP-CRA results and the clinical response and progression-free survival.
Results: Patients were dichotomized into the SG (19 patients) and RG (5 patients) groups. There was no difference between groups, in terms of regimen, frequency and interval of chemotherapy. The disease control rate after first response evaluation was not shown statistically difference (89.5% in SG and 60.0% in RG, respectively, P=0.15). And there was also no significance in second and third response evaluation. The median progression-free month were 7.0 (range, 2–27 month) and 5.0 (range, 3–12 month), respectively and shown marginal significance. However, there was no statistical difference in progression-free survival curve (P=0.16). Sensitivity, specificity, positive prediction rate and negative prediction rage for disease control after first response was 85.0%, 50.0%, 89.5%, and 40.0%.
Conclusion: Although ATP-CRA may be helpful in predicting chemotherapy response in metastatic colorectal cancer, there was not conclusive. Therefore, we recommend further clinical studies to confirm the efficacy of chemoresponse assay for metastatic colorectal cancer.
목차
서론
방법
결과
고찰
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Cancer Research and Treatment
2016 .01
-
[Colorectal] What is the Role of Adjuvant Chemotherapy in Elderly Patients with Colorectal Cancer?
대한외과학회 학술대회 초록집
2022 .11
-
항암화학요법을 받는 대장암 환자의 증상경험과 삶의 질
Asian Oncology Nursing
2022 .09
-
Colorectal Cancer
대한외과학회 학술대회 초록집
2022 .11
-
Colorectal Cancer
대한외과학회 학술대회 초록집
2022 .11
-
Colorectal Cancer
대한외과학회 학술대회 초록집
2020 .11
-
Colorectal cancer
대한외과학회 학술대회 초록집
2015 .11
-
Colorectal Cancer
대한외과학회 학술대회 초록집
2021 .11
-
Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells
Immune Network
2016 .04
-
Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Guideline of Adjuvant Chemotherapy - Colorectal Cancer
대한외과학회 학술대회 초록집
2017 .11
-
Expansion of surgeon"s role in chemotherapy for colorectal cancer
대한임상종양학회 학술대회지
2022 .02
-
휴대용 항암 주입기 동영상 교육이 대장암 환자의 지식, 자기효능감 및 불안에 미치는 효과
Asian Oncology Nursing
2022 .09
-
Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage Ⅲ colorectal cancer
Annals of Surgical Treatment and Research
2019 .08
-
췌장 및 담도암 환자의 항암 시작, 반응 평가 및 항암 중단 시점
대한췌담도학회지
2020 .01
-
[Colorectal] A Multicenter Study of Clinicopathological Outcomes in Young Adult Patients with Colorectal Cancer: Prognostic Effect of Chemotherapy
대한외과학회 학술대회 초록집
2022 .11
-
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Colorectal Cancer Patient Characteristics, Treatment and Survival in Oman - a Single Center Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Prediction of the response to neoadjuvant chemotherapy for colorectal cancer with liver metastasis patients by 3D reconstruction of Computed Tomography images
대한외과학회 학술대회 초록집
2019 .10
-
Identify the important features by Random Forest Model when deciding the chemotherapy for colorectal cancer patients
대한임상종양학회 학술대회지
2020 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-513-002430241